36476-82-1

Basic information

• Product Name: 1-(DIPHENYLMETHYL)-3-METHOXYAZETIDINE
• Synonyms: 1-(DIPHENYLMETHYL)-3-METHOXYAZETIDINE;1-Benzhydryl-3-methoxy-azetidine;Azetidine, 1-(diphenylMethyl)-3-Methoxy-
• CAS NO: 36476-82-1
• Molecular Formula: C₁₇H₁₉NO
• Molecular Weight: 253.34
• Mol File: 36476-82-1.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 335.1 °C at 760 mmHg
• Flash Point: 99 °C
• Appearance: /
• Density: 1.11 g/cm³
• Storage Temp.: 2-8°C
• PKA: 6.48±0.10(Predicted)
• CAS DataBase Reference: 1-(DIPHENYLMETHYL)-3-METHOXYAZETIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(DIPHENYLMETHYL)-3-METHOXYAZETIDINE(36476-82-1)
• EPA Substance Registry System: 1-(DIPHENYLMETHYL)-3-METHOXYAZETIDINE(36476-82-1)

Safety Data

• Hazardous Substances Data: 36476-82-1(Hazardous Substances Data)

Usage

General Description

"1-(Diphenylmethyl)-3-methoxyazetidine" is a chemical compound characterized by a structure consisting of an azetidine ring, which is a type of heterocyclic compound. This specific azetidine derivative is further distinguished by a diphenylmethyl group and a methoxy group attached to the ring, which can significantly influence its physical and chemical properties. These include its solubility, melting and boiling points, as well as its reactivity with other substances. Its exact uses may vary depending on its chemical behavior and interaction with other organic and inorganic substances, but like other azetidine derivatives, it is primarily used in research and in the synthesis of pharmaceuticals.

Upstream product

• 776-74-9 Bromodiphenylmethane 
• 91-00-9 Benzhydrylamine 
• 18621-17-5 1-(diphenylmethyl)-3-hydroxyazetidine 
• 74-88-4 methyl iodide 
• 90604-02-7 1-(diphenylmethyl)-3-azetidinol hydrochloride 

Downstream Products

• 1252779-85-3 1-[4-(1-benzhydrylazetidin-3-yl)piperazin-1-yl]-2,2,2-trifluoroethanone 
• 110925-17-2 3-methoxyazetidine 

Relevant articles and documents

Hydrogen Bonding Phase-Transfer Catalysis with Ionic Reactants: Enantioselective Synthesis of γ-Fluoroamines

Ammonium salts are used as phase-Transfer catalysts for fluorination with alkali metal fluorides. We now demonstrate that these organic salts, specifically azetidinium triflates, are suitable substrates for enantioselective ring opening with CsF and a chiral bis-urea catalyst. This process, which highlights the ability of hydrogen bonding phase-Transfer catalysts to couple two ionic reactants, affords enantioenriched γ-fluoroamines in high yields. Mechanistic studies underline the role of the catalyst for phase-Transfer, and computed transition state structures account for the enantioconvergence observed for mixtures of achiral azetidinium diastereomers. The N-substituents in the electrophile influence the reactivity, but the configuration at nitrogen is unimportant for the enantioselectivity.

NOVEL TRIAZINE COMPOUNDS

The present invention relates to novel triazine compounds of formula (1), methods of their preparation, pharmaceutical compositions containing these compounds and the use of these compounds to treat proliferative disorders such as tumors and cancers and also other conditions and disorders related to or associated with dysregulation of PI3 Kinases, PI3 Kinase pathway, mTOR and/ or the mTOR pathway.

PYRAZOLE DERIVATIVES

A compound represented by formula (I): (wherein Ar1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, and sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group, a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.